poster
Frontage Laboratories has developed and validated a highly sensitive, GxP-qualified dPCR-based RCL (replication-competent lentivirus) assay to monitor the safety of clinical samples. Targeting the VSV-G gene, this assay offers absolute quantification with a LoD as low as 0.05 copies/µL. It delivers exceptional accuracy, precision, and cross-platform performance. With industry-leading sensitivity and compliance with FDA guidance, Frontage’s RCL assay ensures robust detection of rare recombination events and supports regulatory submission with exceptional analytical confidence.
Register to gain access to gated resources.
"*" indicates required fields